Skip to content

BFR ESS - A randomized comparative, prospective, multicentre phase II study evaluating the clinical impact of interruption versus maintenance of aromatase inhibitors in patients with locally advanced or metastatic low grade endometrial stromal sarcoma

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-512629-97-00
Acronym
ET17-200
Enrollment
40
Registered
2024-09-19
Start date
2019-01-23
Completion date
Unknown
Last updated
2025-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with locally advanced or metastatic low grade endometrial stroma sarcoma

Brief summary

Progression-Free Survival (PFS), defined as the time from date of randomization to date of the first documented radiological progression (RECIST 1.1) or death due to any cause.

Detailed description

Between arms: ✓ the overall survival (OS)✓ the safety, ✓ the Quality of Life (QoL), ✓ the time to first subsequent chemotherapy;, The progression-free survival (PFS) after AI reintroduction in the experimental arm, The objective response rate (ORR) after reintroduction of AI in the experimental arm, The duration of response to AI after reintroduction in the experimental arm.

Interventions

DRUGAROMASINE 25 mg
DRUGcomprimé pelliculé
DRUGLETROZOLE

Sponsors

Centre Leon Berard
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Progression-Free Survival (PFS), defined as the time from date of randomization to date of the first documented radiological progression (RECIST 1.1) or death due to any cause.

Secondary

MeasureTime frame
Between arms: ✓ the overall survival (OS)✓ the safety, ✓ the Quality of Life (QoL), ✓ the time to first subsequent chemotherapy;, The progression-free survival (PFS) after AI reintroduction in the experimental arm, The objective response rate (ORR) after reintroduction of AI in the experimental arm, The duration of response to AI after reintroduction in the experimental arm.

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026